Skip to main content
Top
Published in: World Journal of Surgery 5/2007

01-05-2007 | Invited Commentary

From Genetic Testing to the Operating Room

Author: Terry C. Lairmore, MD, FACS

Published in: World Journal of Surgery | Issue 5/2007

Login to get access

Excerpt

Cancer is a genetic disease, resulting in simplistic terms from an accumulation of genetic changes within a cell that render it unresponsive to the normal controls for cell growth, repair or programmed death. The detection of a specific gene change conferring an inherited cancer risk can now be accomplished by direct genetic testing for patients with a number of familial cancer syndromes. In these uncommon disorders, a genetic mutation occurs in a critical gene, and the error is inherited in the germline (and therefore present in one allelic copy of the gene in every cell). Furthermore, it has been recognized that the chance occurrence of one or more of these defects in a somatic cell can contribute to the more common sporadic tumors that arise in the same target tissues. Increasingly, cancers are being characterized at the molecular level, and the number and nature of these genetic changes can be correlated with the biologic behavior of the cancer and its prognosis, or may identify an optimal targeted therapy. As genetic diagnosis extends from identifying risk for rare hereditary cancers to testing for more common genetic variants that are associated with increased cancer risk, there is a need to address these complex issues to maximize the benefits of genetic testing1. …
Literature
1.
go back to reference Lerman C, Shields AE. Genetic testing for cancer susceptibility: the promise and the pitfalls. Nature Rev Cancer 2004;4:235–241CrossRef Lerman C, Shields AE. Genetic testing for cancer susceptibility: the promise and the pitfalls. Nature Rev Cancer 2004;4:235–241CrossRef
2.
go back to reference Gimm O, Ukkat J, Niederle BE, Weber T, Thanh PN, Brauckhoff M, Niederle B, Dralle H. Timing and extent of surgery in patients with familial medullary carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634. World J Surg 2004;28:1312CrossRefPubMed Gimm O, Ukkat J, Niederle BE, Weber T, Thanh PN, Brauckhoff M, Niederle B, Dralle H. Timing and extent of surgery in patients with familial medullary carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634. World J Surg 2004;28:1312CrossRefPubMed
3.
go back to reference Wells SA Jr, Chi DD, Toshima K, Dehner LP, Coffin CM, Dowton SB, Ivanovich JL, DeBenedetti MK, Dilley WG, Moley JF, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994;220:237–247CrossRefPubMed Wells SA Jr, Chi DD, Toshima K, Dehner LP, Coffin CM, Dowton SB, Ivanovich JL, DeBenedetti MK, Dilley WG, Moley JF, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994;220:237–247CrossRefPubMed
4.
go back to reference Skinner MA, Moley JF, Dilley WG, Owzar K, DeBenedetti MK, Wells SA Jr. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 2005;353:1105–1113CrossRefPubMed Skinner MA, Moley JF, Dilley WG, Owzar K, DeBenedetti MK, Wells SA Jr. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 2005;353:1105–1113CrossRefPubMed
Metadata
Title
From Genetic Testing to the Operating Room
Author
Terry C. Lairmore, MD, FACS
Publication date
01-05-2007
Publisher
Springer-Verlag
Published in
World Journal of Surgery / Issue 5/2007
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-007-9038-y

Other articles of this Issue 5/2007

World Journal of Surgery 5/2007 Go to the issue